Table 1.
Examples of some epigenetic trials in various cancers
| Trial (ClinicalTrials.gov) | Drug | Combination | Target | Study phase | Indication |
|---|---|---|---|---|---|
| NCT01034163 | Panobinostat (LBH589) | None | Pan-HDAC inhibitor | Phase III | Hodgkin’s lymphoma and multiple myeloma |
| NCT01023308 | Bortezomib, dexamethasone | Pan-deacetylase inhibitor | Phase III | Relapsed multiple myeloma | |
| NCT00425555 | None | Phase II/III | Cutaneous T cell lymphoma | ||
| NCT00866333 | Entinostat (SNDX-275) | None | Class I HDAC inhibitor | Phase I/II | Hodgkin’s lymphoma, kidney cancer |
| NCT01038778 | None | Phase II | Clear cell renal cell carcinoma, metastatic renal cell cancer | ||
| NCT01349959 | Azacitidine | Phase II | Advanced breast cancer | ||
| NCT00357032 (Completed) | Belinostat (PXD101) | None | Pan-HDAC inhibitor | Phase II | Relapsed or refractory acute myeloid leukemia or older patients with newly diagnosed acute myeloid leukemia |
| NCT01310244 | Carboplatin, paclitaxel | HDAC inhibitor | Phase I/II | Non–small cell lung cancer | |
| NCT00274651 | None | Phase II | Recurrent or refractory cutaneous and peripheral T cell lymphomas | ||
| NCT00301756 | None | Phase II | Ovarian cancer | ||
| NCT01873703 | Pracinostat (SB939) | Azacitidine | HDAC inhibitor | Phase II | Myelodysplastic syndrome |
| NCT01912274 | Azacitidine | Phase II | Acute myeloid leukemia | ||
| NCT01112384 (Completed) | None | Phase II | Translocation-associated recurrent/metastatic sarcomas | ||
| NCT01761968 | Givinostat | None | HDAC inhibitor | Phase II | Chronic myeloproliferative neoplasms |
| NCT01900730 | Valproic acid | None | HDAC inhibitor | Phase II | Breast cancer |
| NCT00477386 | Carboplatin | Decitabine | Demethylation | Phase I/II | Platinum-resistant ovarian cancer |
| NCT00387465 | Entinostat | Azacitidine | HDAC inhibitor | Phase I/II | Recurrent advanced non–small cell lung cancer |
| NCT01105377 | Entinostat | Azacitidine | HDAC inhibitor | Phase II | Metastatic colorectal cancer |
| NCT02115282 | Exemestane with or without | Entinostat | HDAC inhibitor | Phase III | Recurrent hormone receptor-positive breast cancer that is locally advanced or metastatic |
| NCT00091559 | Vorinostat | None | HDAC inhibitor | Phase II | Advanced cutaneous T cell lymphoma |
| NCT00275080 | Vorinostat | Decitabine | HDAC inhibitor | Phase I | Advanced solid tumors or relapsed or refractory non-Hodgkin’s lymphoma |
| NCT00071799 | Azacitidine | None | Demethylation | Phase III | High-risk myelodysplastic syndromes comparing azacitidine versus conventional care |
| NCT00007345 | Romidepsin | None | HDAC inhibitor | Phase II | Cutaneous T cell lymphoma and peripheral T cell lymphoma |
Abbreviation: HDAC, histone deacetylase.